1. At a Glance – Africa Calling, Khopoli Building, Bonus Flying
At ₹327 per share and a market cap of ₹572 crore, Kilitch Drugs (India) Ltd is not a sleepy microcap anymore — it’s that small pharma player that suddenly decided to announce a 1:1 bonus and a ₹100 crore greenfield plant like it just won the lottery.
Latest quarterly (Q3 FY26 – Dec 2025) numbers show:
- Sales: ₹53.81 crore
- PAT: ₹4.31 crore
- EPS: ₹2.53
- Stock P/E: 21.9
- ROCE: 15.7%
- ROE: 12.6%
- Debt to Equity: 0.31
- 3-Month Return: -8.21%
So here’s the drama:
Profit down 25.7% YoY.
Sales down 4.2% YoY.
But management says: “Let’s do a 1:1 bonus.”
Are they confident? Overconfident? Or just riding the Africa export wave?
And with a ₹50 crore rights issue already done, authorised capital increase approved, and Khopoli plant under construction — this company clearly doesn’t believe in small moves.
Question is:
Is this expansion bold strategy… or ambitious overreach?
Let’s investigate like a slightly suspicious auditor with a sense of humour.
2. Introduction – From 1978 to Ethiopia
Incorporated in 1978, Kilitch Drugs has been in pharma long enough to remember when prescriptions were handwritten in cursive and doctors didn’t Google symptoms.
The company operates in:
- Solid dosage
- Liquid formulations
- Parenterals
- Effervescents
- Medical devices
- Cosmetics
- Herbal products
Basically, if it goes inside your body or on your skin, they probably manufacture it.
But here’s where it gets interesting:
Exports form ~59% of FY23 revenue.
Africa is their playground.
They even have a manufacturing facility in Ethiopia through Kilitch Estro Biotech PLC (67% ownership). And that Ethiopian subsidiary bagged a tender worth USD 9.13 million in February 2024 from the Federal Democratic Republic of Ethiopia Pharmaceutical Supply Service.
Translation:
This is not just a local generic seller. It’s an export-driven small pharma trying to punch above its weight.
Now combine that with:
- ₹100 crore greenfield project at Khopoli (commercial ops expected by 2025)
- ₹50 crore rights issue
- 1:1 bonus issue approved in Feb 2026
That’s a lot of financial fireworks for a ₹572 crore company.
But are the fundamentals matching the ambition?
Let’s dissect.
3. Business Model – WTF Do They Even Do?
Imagine explaining Kilitch to a lazy investor friend.
“Bro,
